Trials / Unknown
UnknownNCT02981212
Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid in Advanced IgA Nephropathy
Multi-center, Randomized, Open Label, Comparative, Phase IV Study to Evaluate the Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid for 48 Weeks in Advanced IgA Nephropathy
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Yonsei University · Academic / Other
- Sex
- All
- Age
- 19 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this clinical study is to evaluate the efficacy and safety of that test group was administered with Mycophenolate Mofetil in combination with corticosteroid in patients with advanced IgA nephropathy. The control group will be observed for up to 48 weeks without administration of Mycophenolate Mofetil.
Detailed description
The subject who signed the written agreement to participate in the clinical trial evaluates the conformity and then 1: 1 randomly allocated. The study group were taken 48 weeks with MYREPT ® capsules in combination with corticosteroids and the control group were asked to preserve the conservative treatment regimen prior to the clinical trial registration Maintenance. The subject who started taking the study medicine will carry out the examination and procedure if it has to be carried out for the visit via outpatient clinic at 4 weeks, 12 weeks, 24 weeks, 36 weeks, 48 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mycophenolate Mofetil | less than 80 kg: 1,500 mg / day , 80 kg or more: 2,000 mg / day divided twice a day and administered orally |
| DRUG | ACE inhibitor | maintain conservative treatment (using ACE inhibitor or ARB for blood pressure regulation and proteinuria suppression treatment) just as before randomization |
| DRUG | Corticosteroid | combination with Mycophenolate Mofetil |
| DRUG | ARB | maintain conservative treatment (using ACE inhibitor or ARB for blood pressure regulation and proteinuria suppression treatment) just as before randomization |
Timeline
- Start date
- 2016-06-01
- Primary completion
- 2018-08-01
- Completion
- 2018-10-01
- First posted
- 2016-12-05
- Last updated
- 2016-12-05
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02981212. Inclusion in this directory is not an endorsement.